Showing 1 - 20 results of 28 for search '"ФОТОДИНАМИЧЕСКАЯ ДИАГНОСТИКА"', query time: 0.77s Refine Results
  1. 1
    Academic Journal

    Source: Research and Practical Medicine Journal; Том 7, № 2 (2020); 129-143 ; Research'n Practical Medicine Journal; Том 7, № 2 (2020); 129-143 ; 2410-1893 ; 10.17709/2409-2231-2020-7-2

    File Description: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/546/365; Состояние онкологической помощи населению России в 2018 году под редакцией А.Д. Каприна, В.В. Старинского, Г.В. Петровой, 2019.; Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC Cancer Staging Manual, 8th ed. Springer International Publishing: New York; 2017. Available from: https://www.springer.com/gp/book/9783319406176; Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) — 2019 Update. Eur Urol. 2019 Nov; 76(5): 639–657. https://doi.org/10.1016/j.eururo.2019.08.016; Алексеев Б. Я., Андронов А. С., Атдуев В. А., Байков Н. А., Важенин А. В., Васильев О.Н. и др. Рак мочевого пузыря (классика и новации). Медфорум. Монография. Москва, 2017, 262 с.; Иванов С.А., Заборский И.Н., Чайков В.С. Лечение немышечно-инвазивного рака мочевого пузыря высокого риска. Вестник Урологии. 2017; 5(2): 42–49. https://doi.org/10.21886/2308–6424–2017–5-2–42–49; Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017; 71(3): 447–461. https://doi.org/10.1016/j.eururo.2016.05.041; Geavlete B, Multescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors-results of a prospective, randomized comparison to the standard approach. Urology. 2012 Apr; 79(4): 846–851. https://doi.org/10.1016/j.urology.2011.08.081; Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, et al. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol. 2014 Oct; 11(10): 589–596. https://doi.org/10.1038/nrurol.2014.245; Malmström P‐U, Agrawal S, Bläckberg M, Boström PJ, Malavaud B, Zaak D, et al. Non-muscle-invasive bladder cancer: a vision for the future. Scand J Urol. 2017 Apr; 51(2): 87–94. https://doi.org/10.1080/21681805.2017.1283359; Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int. 2011 Dec; 108(11): 1703–1707. https://doi.org/10.1111/j.1464–410X.2011.10485.x; Лоран О.Б., Серегин А.В., Дадашев Э.О., Бабаев А.Б., Лощенов В.Б. Фотодинамическая диагностика отечественной флуоресцентной видеосистемой неинвазивного рака мочевого пузыря. Consilium Medicum. 2018; 20(7): 37–40. https://doi.org/10.26442/2075–1753_2018.7.37–40; Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013 Nov; 64(5): 846–854. https://doi.org/10.1016/j.eururo.2013.03.059; Kamat A, Cookson M, Witjes JA, Stenzl A, Grossman HB. TheImpact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer — A New Analysis. Bladder Cancer. 2016 Apr 27; 2(2): 273–278. https://doi.org/10.3233/BLC-160048; Daneshmand S, Bazargani ST, Bivalacqua TJ, Holzbeierlein JM, Willard B, Taylor JM, et al. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. Urol Oncol. 2018; 36(8): 361.e1–361.e6. https://doi.org/10.1016/j.urolonc.2018.04.013; Gallagher KM, Gray K, Anderson CH, Lee H, Stewart S, Donat R, et al. “Real-life experience”: recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study. World J Urol. 2017 Dec; 35(12): 1871–1877. https:// doi.org/10.1007/s00345–017–2077–6; Bach T, Bastian PJ, Blana A, Kaminsky A, Keller S, Knoll T, et al. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III. World J Urol. 2017 May; 35(5): 737–744. https://doi.org/10.1007/s00345–016–1925–0; Pagliarulo V, Alba S, Gallone MF, Di Stasi S, Cormio L, Petitti T, et al. Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy. J Endourol. 2017; 31(4): 405–411. https://doi.org/10.1089/end.2016.0804; Drăgoescu PO, Tudorache Ş, Drocaş AI, Mitroi G, Pănuş A, Drăgoescu NAM, et al. Improved diagnosis and long-term recurrence rate reduction for non-muscle-invasive bladder cancer patients undergoing fluorescent hexylaminolevulinate photodynamic diagnosis. Rom J Morphol Embryol. 2017; 58(4): 1279–1283.; Lykke MR, Nielsen TK, Ebbensgaard NA, Zieger K. Reducing recurrence in non-muscle-invasive bladder cancer using photodynamic diagnosis and immediate post-transurethral resection of the bladder chemoprophylaxis. Scand J Urol. 2015 Jun; 49(3): 230–236. https://doi.org/10.3109/21681805.2015.1019562; Kata SG, Zreik A, Ahmad S, Chłosta P, Aboumarzouk O. Concurrent bladder cancer in patients undergoing photodynamic diagnostic ureterorenoscopy: how many lesions do we miss under white light cystoscopy? Cent European J Urol. 2016; 69(4): 334–340. https://doi.org/10.5173/ceju.2016.896; Kim SB, Yoon SG, Tae J, Kim JY, Shim JS, Kang SG, et al. Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investig Clin Urol. 2018; 59(2): 98–105. https://doi.org/10.4111/icu.2018.59.2.98; Drejer D, Béji S, Oezeke R, Nielsen AM, Høyer S, Bjerklund Johansen TE, et al. Comparison of White Light, Photodynamic Diagnosis, and Narrow-band Imaging in Detection of Carcinoma In Situ or Flat Dysplasia at Transurethral Resection of the Bladder: the DaBlaCa 8 Study. Urology. 2017; 102: 138–142. https://doi.org/10.1016/j.urology.2016.11.032; Naito S, Algaba F, Babjuk M, Bryan RT, Sun Y H, Valiquette L, et al. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1 year Results. Eur Urol. 2016; 70(3): 506–515. https://doi.org/10.1016/j.eururo.2016.03.053; Xiong Y, Li J, Ma S, Ge J, Zhou L, Li D, et al. A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS ONE. 2017; 12(2): e0170819. https://doi.org/10.1371/journal.pone.0170819; Bryan RT, Shah ZH, Collins SI, Wallace DMA. Narrow-bandimaging flexible cystoscopy: a new user’s experience. J Endourol. 2010 Aug; 24(8): 1339–1343. https://doi.org/10.1089/end.2009.0598; Kang W, Cui Z, Chen Q, Zhang D, Zhang H, Jin X. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis. Oncotarget. 2017 Apr 4; 8(14): 23880. https://doi.org/10.18632/oncotarget.13054; Geavlete BF, Brînzea A, ChecheriŢă IA, Zurac SA, GeorgescuDA, Bastian AE, et al. Carcinoma in situ of the urinary bladder — from pathology to narrow band imaging. Rom J Morphol Embryol. 2015; 56(3): 1069–1076.; Lee JY, Cho KS, Kang DH, Jung HD, Kwon JK, Oh CK, et al. A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5 aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer. 2015 Aug 1; 15: 566. https://doi.org/10.1186/s12885–015–1571–8; Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Optical coherence tomography. Science. 1991 Nov 22; 254(5035): 1178–1181. https://doi.org/10.1126/science.1957169; Huang J, Ma X, Zhang L, Jia H, Wang F. Diagnostic accuracy of optical coherence tomography in bladder cancer patients: A systematic review and meta-analysis. Mol Clin Oncol. 2018 Apr; 8(4): 609–612. https://doi.org/10.3892/mco.2018.1566; Xiong YQ, Tan J, Liu Y M, Li Y Z, You F F, Zhang M Y, et al. Diagnostic accuracy of optical coherence tomography for bladder cancer: A systematic review and meta-analysis. Photodiagnosis Photodyn Ther. 2019 Sep; 27: 298–304. https://doi.org/10.1016/j.pdpdt.2019.06.006; Lerner SP, Goh A. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015 Jan 15; 121(2): 169–178. https://doi.org/10.1002/cncr.28905; Chang TC, Liu J J, Hsiao ST, Pan Y, Mach KE, Leppert JT, et al. Interobserver agreement of confocal laser endomicroscopy for bladder cancer. J Endourol. 2013 May; 27(5): 598–603. https://doi.org/10.1089/end.2012.0549; Liem EI, Freund JE, Baard J, de Bruin DM, Laguna Pes MP, Savci-Heijink CD, et al. Confocal Laser Endomicroscopy for the Diagnosis of Urothelial Carcinoma in the Bladder and the Upper Urinary Tract: Protocols for Two Prospective Explorative Studies. JMIR Res Protoc. 2018 Feb 7; 7(2): e34. https://doi.org/10.2196/resprot.8862; Rao AR, Hanchanale V, Javle P, Karim O, Motiwala H. Spectroscopic view of life and work of the Nobel Laureate Sir C.V. Raman. J Endourol. 2007 Jan; 21(1): 8–11. https://doi.org/10.1089/end.2006.9998; Schäfauer C, Ettori D, Rouprêt M, Phé V, Tualle J M, Tinet E, et al. Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study. J Urol. 2013 Jul; 190(1): 271–277. https://doi.org/10.1016/j.juro.2013.01.100; Zipfel WR, Williams RM, Webb WW. Nonlinear magic: multiphoton microscopy in the biosciences. Nat Biotechnol. 2003 Nov; 21(11): 1369–1377. https://doi.org/10.1038/nbt899; Jain M, Robinson BD, Scherr DS, Sterling J, Lee M–M, Wysock J, et al. Multiphoton microscopy in the evaluation of human bladder biopsies. Arch Pathol Lab Med. 2012 May; 136(5): 517–526. https://doi.org/10.5858/arpa.2011–0147-OA; Tewari AK, Shevchuk MM, Sterling J, Grover S, Herman M, Yadav R, et al. Multiphoton microscopy for structure identification in human prostate and periprostatic tissue: implications in prostate cancer surgery. BJU Int. 2011 Nov; 108(9): 1421–1429. https://doi.org/10.1111/j.1464–410X.2011.10169.x; Rivera DR, Brown CM, Ouzounov DG, Pavlova I, Kobat D, Webb WW, et al. Compact and flexible raster scanning multiphoton endoscope capable of imaging unstained tissue. Proc Natl Acad Sci USA. 2011 Oct 25; 108(43): 17598–17603. https://doi.org/10.1073/pnas.1114746108; Seibel EJ, Brentnall TA, Dominitz JA. New endoscopic and cytologic tools for cancer surveillance in the digestive tract. Gastrointest Endosc Clin N Am. 2009 Apr; 19(2): 299–307. https://doi.org/10.1016/j.giec.2009.02.002; Seibel EJ, Brown CM, Dominitz JA, Kimmey MB. Scanning single fiber endoscopy: a new platform technology for integrated laser imaging, diagnosis, and future therapies. Gastrointest Endosc Clin N Am. 2008 Jul; 18(3): 467–478, viii. https://doi.org/10.1016/j.giec.2008.05.001; Yoon WJ, Park S, Reinhall PG, Seibel EJ. Development of an Automated Steering Mechanism for Bladder Urothelium Surveillance. J Med Device. 2009 Mar 1; 3(1): 11004. https://doi.org/10.1115/1.3054381; https://www.rpmj.ru/rpmj/article/view/546

  2. 2
  3. 3
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 11 (2019); 195-199 ; Медицинский Совет; № 11 (2019); 195-199 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-11

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/3103/3023; Филоненко Е.В. Флюоресцентная диагностика и фотодинамическая терапия в онкологии. Автореф. дисс. докт. мед. Наук. ФГУ «Московский научно-исследовательский онкологический институт». Москва, 2006.; Policard A. Etude sur les aspects offerts par des tumeurs experimentales examinees a la lumiere de Wood. C R Soc Biol 1924;91:1423-4.; Auler H, Banzer G. Untersuchungen ueber die Rolle der Porphyrine bei geschwulskranken Menschen und Tieren. Z Krebsforsch. 1942;53:65-8.; Figge H.J, Weiland GS, Manganiello LJ. Cancer detection and therapy, affinity of neoplastic, embryonic, and traumatized tissues for porphyrins and metalloporphyrins. Proc Soc Exp Boil Med. 1948;68:640-1.; Peck, G.C., H.P. Mack and W.A. Holbrook. Use of hematoporphyrin fluorescence in biliary and cancer surgery. Ann. Surg’. 1955;21:181-188.; Gray M.J., R.L Lipson, J.V.S. Maeck, L. Parker and D. Romeyn. (1967) Use of hematoporphyrin derivative in detection and management of cervical cancer: Am. Jv Obstet-Gynecor, 1999;766-77.; Leonard J.R. and W.L. Beck. Hematoporphyrin iluorescence: an aid to diagnosis of malignant neoplasms. Laryngoscope 81:365-372.; Profio A.E. and D.R. Doiron. Laser fluorescence bronchoscope for localization of occult lung tumours. Med. Phys. 6:523-525.; Hayata Y., H. Kato, C. Konaka, J. Ono, Y. Matsushima, K. Yoneyama and K. Nishimiya. Fiberoptic bronchoscopic laser photoradiation for tumor localization in lung cancer. Chest 1982;82:10-14.; Kennedy J.C., Pottier R.H., Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J. Photophem. Photobiol. 1990;6: 143-148.; Гаращенко Т.И. Современные достижения в лечении ювенильного папилломатоза гортани у детей и дальнейшие пути его совершенствования. Материалы VIII съезда педиатров России, М., 1998, С. 222-223; Соколов В.В. Комбинированная эндоларингеальная видеоэндоскопическая хирургия и фотодинамическая терапия больных с рецидивирующим папилломатозом гортани и трахеи. Вестник оториноларингологии. М-во здравоохранения РФ, Всероссийское общество оториноларингологов, ТОО «Яртек Медикал». 2007;6:4-9.; Tochner AZ, Pass Hi; Smith PD, DeLaney TF, Sprague M. DeLuca AM. et al. Intrathoracic photodynamic therapy: a canine normal tissue tolerance study and early clinical experience. Lasers Surg Med. 1994;14:118-23; Lightdale C.I, Heier SK, Marcon NE, McCoughan JS Jr., Gerdes H. Over-holt BF, et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial, Gastromtest Endose 1995;42:507-12.

  4. 4
    Academic Journal

    Source: Cancer Urology; Том 12, № 3 (2016); 58-67 ; Онкоурология; Том 12, № 3 (2016); 58-67 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-3

    File Description: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/538/597; https://oncourology.abvpress.ru/oncur/article/view/538/645; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/538/184; Falke J, Witjes JA. Contemporary management of low-risk bladder cancer. Nat Rev Urol. 2011 Jan;8(1):42-9.; Orsola A, Palou J, Solsona E. High-risk nonmuscle invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr;29(2):227-36.; van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011 Sep;60(3):493-500.; Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014 Apr;65(4):778-92.; Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007 Apr;177(4):1283-6.; Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000 Apr;163(4):1124-9.; Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013 Mar;63(3):462-72.; Мохорт, А.А. Применение препарата "Аламин" для фотодинамической диагностики рака мочевого пузыря. Здравоохранение: научно-практический ежемесячный журнал. - 2007. - N11. - С. 73-75.; Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2015 Jul 22. pii: S0302-2838(15)00556-4. doi:10.1016/j.eururo.2015.06.045. [Epub ahead of print]; Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995 Jun;13(6):1404-8.; Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol. 1997 Nov;80(5):762-5.; Patard JJ, Rodriguez A, Leray E, et al. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol. 2002 Jun;41(6):635-41.; Shahin O, Thalmann GN, Rentsch C, et al. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003 Jan;169(1):96-100.; Malmström PU, Wijkström H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999 Apr;161(4):1124-7.; Gårdmark T, Jahnson S, Wahlquist R, et al. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int. 2007 Apr;99(4):817-20.; Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004 Mar;93(4):485-90.; Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009 Aug;56(2):247-56.; Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010 May;57(5):766-73.; Palou J, Laguna P, Millán-Rodríguez F, et al. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol. 2001 May;165(5):1488-91.; Oddens JR, Sylvester RJ, Brausi MA, et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol. 2014 Oct;66(4):694-701.; Yuan H, Qiu J, Liu L, et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One. 2013 Sep 13;8(9):e74142.; Daniltchenko DI, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005 Dec;174(6):2129-33.; Denzinger S, Burger M, Walter B, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007 Apr;69(4):675-9.; Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-5.; Martin-Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol. 2015 Feb 20;33(6):643-50.; https://oncourology.abvpress.ru/oncur/article/view/538

  5. 5
  6. 6
    Academic Journal

    Source: Bulletin of Siberian Medicine; Том 11, № 2 (2012); 110-114 ; Бюллетень сибирской медицины; Том 11, № 2 (2012); 110-114 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2012-11-2

    File Description: application/pdf

    Relation: https://bulletin.tomsk.ru/jour/article/view/460/449; Велиев Е.И., Петров С.Б., Лоран О.Б. Частота и локализация позитивного хирургического края и его роль в прогнозировании рецидива рака предстательной железы // Урология. 2004. № 6. С. 19—21.; Делекторская Л.Н., Пименова Л.М., Кадашева О.Г. Оценка диагностической информативности лабораторных тестов (методические рекомендации) // Клинич. лаб. диагностика. 1992. № 1. С. 49—59.; Злокачественные новообразования в России в 2009 году (заболеваемость и смертность) / под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: ФГУ «МНИОИ им. П.А. Герцена Росмедтехнологий», 2011. 260 с.; Петров С.Б., Ракул С.А. Положительный хирургический край при радикальной позадилонной простатэктомии: частота, прогностические факторы, медикаментозная профилактика // Онкоурология. 2006. № 1. С. 40—44.; Соколов В.В., Чиссов В.И., Филоненко Е.В. и др. Флуоресцентная диагностика и фотодинамическая терапия с препаратами «Фотосенс» и «Аласенс»: опыт 11-летнего клинического применения // Рос. биотерапевт. журн. 2006. Т. 5, № 1. С. 32—33.; Ackerman D.A., Barry J.M., Wicklund R.A. et al. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy // J. Urol. 1993. V. 150, № 6. Р. 1845—1850.; Cheng L.D., Darson M.F., Bergstralh E.J. et al. Correlation of margin status and extraprostatic extension with progres-; sion of prostate carcinoma // Cancer. 1999. V. 86, № 9. Р. 1775—1782.; Eastham J.A., Kattan M.W., Riedel E. et al. Variations among individual surgions in the rate of positive surgical margins in radical prostatectomy specimens // J. Urol. 2003. V. 170, № 4. Р. 2292—2295.; Epstein J.I. Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive // Am. J. Surg. Pathol. 1990. V. 14, № 7. Р. 626—632.; Mazzucchelli R., Santinelli A., Lopez-Beltran A. et al. Evaluation of prognostic factors in radical prostatectomy specimens with cancer // Urol. Int. 2002. V. 68, № 4. P. 209—215.; O’Dowd G.J., Veltri R.W., Orozco R. et al. Update on the appropriate staging evaluation fro newly diagnosed prostate cancer // J. Urol. 1997. V. 158, № 6. Р. 687—698.; Ojea C.A., Gonzalez P.A., Dominguez F.F. Prognostic implications of positive margins in radical prostatectomy specimens // Actas Urol. Esp. 2005. V. 29, № 7. P. 641—647.; Pettus J.A., Weight C.J., Thompson C.J. et al. Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location // J. Urol. 2004. V. 171, № 1. Р. 129—132.; Sofer M., Hamilton-Nelson K.L., Cavintos F. et al. Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression // J. Urol. 2002. V. 167, № 6. P. 2453—2456.; Swindle P., Eastham J.A., Ohori M. et al. Do margins mat-ter? The prognostic significance of positive surgical margins in radical prostatectomy specimens // J. Urol. 2005. V. 174, № 3. Р. 903—907.; Walsh P.C., Donker P.J. Impotance following radical prosta-tectomy: insight into etiology and prevention // J. Urol. 1982. V. 128, № 2. P. 492—497.; Wieder J.A., Soloway M.S. Incidence, etiology, location, prevention and treatment of positive surgical margin after radical prostatectomy // J. Urol. 1998. V. 160, № 1. Р. 299—315.; Weldon V.E., Tavel F.R., Neuwirth H. et al. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy // J. Urol. 1995. V. 153, № 5. P. 1565—1569.; https://bulletin.tomsk.ru/jour/article/view/460

  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
    Academic Journal

    Source: Cancer Urology; Том 7, № 3 (2011); 80-84 ; Онкоурология; Том 7, № 3 (2011); 80-84 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2011-7-3

    File Description: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/239/256; Аполихин О.И, Сивков А.В., Бешлиев Д.А. и др. Анализ уронефрологической заболеваемости в Российской Федерации по данным официальной статистики. Экспер и клинич урол 2010;(1):4−11.; Заболеваемость населения России в 2006 году: Статистические материалы: в II ч. М., 2007 (электронная версия МЗиCP РФ и ЦНИИ организации и инфор матизации здравоохранения МЗиCP РФ).; American Cancer Society. Cancer facts and figures 2007 — Atlanta. American Cancer Sosiety 2007. 72 p.; Sobin D.H., Wittekind C.H., editors. TNM classification of malignant tumors, ed. 6-th. New York: Wiley-Liss, 2002; p. 199−202.; Oosterlinck W., Witres F., Sylvester R. Diagnostic and Prognostic Factors in Non-Muscle-Invasive Bladder Cancer and Their Influence on Treatment and Outcomes. Eur Urol 2008;4:321−4.; Sylvester R., Kurth K., Denis L. et al. Predicting the short-term and long-term prognosis of patients with Та Tl bladder cancer: Results of EORTC/MRC randomised clinical trials. Eur Urol 2001;39:471−80.; Thomas K., O'Brien T. Improving transurethral resection of bladder tumor: the gold standard for diagnosis and treatment of bladder tumors. Eur Urol 2008; 4:328−30.; Горелов С.И., Хейфец В.Х., Каган О.Ф. Метод флюоресцентной цистоскопии и его применение в диагностике поверхностного рака мочевого пузыря. Пособие для врачей. СПб., 2004. 32 с.; Матвеев Б.П., Бухаркин Б.В., Кудашев Б.В. и др. Использование визуального и спектрального анализов флюоресценции АЛК-индуцированного протопорфирина IX с целью повышения радикальности трансуретральных резекций мочевого пузыря. Лазер мед 2000;11(5):29−31.; Fradet Y., Grossman H.B., Gomella L. et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white-light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007;178:68−73.; Van der Meijden А.М., Sylvester R, Oosterlinck W. et al. EAU guidelines on the diagnosis and treatment of urothe lial carcinoma in situ. Eur Urol 2005; 48:361−71. 12. Friedrich M.G., Pichlmeier U., Schwaibold H. et al. Long-term intravesical adjuvant chemother apy further reduces the recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 2007;52:1123−30.; Sylvester R.J, Oosterlinck W., van der Meijden А.М. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Та Т1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186 90.; Au J.S., Badalament R.A., Wientjes M.G. et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.J Nat Cancer Inst 2001;93:597−604.; Странадко Е. Ф. Исторический очерк развития фотодинамической терапии: Обзор. Лазер мед 2002(4):4−8.; Bamett A.A., Hatte J.C., Cairnduff F. et al. A randomised, double-blind, placebocontrolled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia. Int J Cancer 2003; 103:829−32.; Странадко Е. Ф. Механизмы действия фотодинамической терапии. III Всероссийский симпозиум «Фотодинамическая терапия»: Сб. М., 1999; с. 3−15.; Moan J., Peng Q., Iani V. et al. Biodistribution, pharmacokinetic and in vivo fluorescence spectroscopic studies of photo sensitizers. SPIE 1995; 2625:234−48.; Странадко Е.Ф. Экспериментально-клиническая разработка метода лазерной фотодинамической терапии злокачественных опухолей с использованием отечественных фотосенсибилизаторов первого и второго поколения. Лазер маркет 1994(11−12):20−6.; Waidelich R., Beyer W., Knuchel R. et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 2003; 61(2):332−7.; Huang Z. A review of progress in clinical photodynamic therapy.Technol Cancer Res Treat 2005;4(3): 283−93.; https://oncourology.abvpress.ru/oncur/article/view/239

  13. 13
  14. 14
  15. 15
    Academic Journal

    Source: Cancer Urology; Том 5, № 4 (2009); 41-46 ; Онкоурология; Том 5, № 4 (2009); 41-46 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-0-3

    File Description: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/296/313; Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году (заболеваемость и смертность). М., 2009.; Матвеев Б.П., Фигурин К.М., Карякин О.Б. Рак мочевого пузыря. М., 2001.; Русаков И.Г., Быстров А.А. Хирургическое лечение, химио- и иммунотерапия больных поверхностным раком мочевого пузыря. Практ онкол 2003;4(4):214—24.; Чиссов В.И., Соколов В.В., Булгакова Н.Н., Филоненко Е.В. Флуоресцентная эндоскопия, дермаскопия и спект рофотометрия в диагностике злокачественных опухолей основных локализаций. Рос биотерапевт журн 2003;2(4):45—56.; Русаков И.Г., Соколов В.В., Булгакова Н.Н. и др. Флуоресцентные методы диагностики и поверхностный рак мочевого пузыря: современное состояние проблемы. Урология 2008;(3):67—71.; Penq Q., Berg K., Moan J. et al. 5-Aminolevulinic acid-based photodynamic therapy: Principles and experimental research. Photochem Photobiol 1997;65:235—51.; Datta S.N., Loh C.S., MacRobert A.J. et al. Quantitative studies of the kinetics of 5- aminolaevulinic acid-induced fluores- cence in bladder transitional cell carcino- ma. Br J Cancer 1998;78:1113—8.; Stepp H., Wagner M., Zaak D., Knuchelclarke R. Fluorescence diagnosis of bladder tumours using 5-ALA — funda- mentals and results. Munich, 1999.; Чиссов В.И., Соколов В.В., Булгако- ва Н.Н. и др. Исследование лазер-индуцированной аутофлуоресценции нормального и неоплазированного уротелия in vivo. Рос онкол журн 2007;(6):18—24.; Zaak D., Kriegmair M., Stepp H. et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001;57:690—4.; Чиссов В.И., Соколов В.В., Жарко- ва Н.Н. и др. Возможности применения флуоресцентной диагностической установки «Спектр-Кластер» в онкологии. В сб.: Материалы Международной конференции и Научно-практической конференции Северо-Западного региона России «Лазерные и информационные технологии в медицине XXI в.». СПб., 2001. с. 513—4.; https://oncourology.abvpress.ru/oncur/article/view/296

  16. 16
  17. 17
  18. 18
  19. 19
  20. 20